Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Allergan : to cut over 1,000 jobs as it works to cut costs

share with twitter share with LinkedIn share with facebook
share via e-mail
01/03/2018 | 08:02pm CET
The Allergan logo is seen in this photo illustration

Botox-maker Allergan Plc on Wednesday said it plans to cut over 1,000 jobs, more than 5 percent of its workforce, and eliminate an additional 400 currently open positions, as it works to cut costs in the face of new competition for its second most important drug, dry-eye treatment Restasis.

The company said the jobs and positions it plans to eliminate mostly focus on products and categories where the company has or expects to soon lose exclusivity.

The drugmaker said it expects to take a $125 million charge from the job cuts, primarily due to severance, most of which will be recorded in the fourth quarter of 2017.

Analysts estimated that the company had around $5.8 billion of net income in 2017 on roughly $15.9 billion of revenue, according to Thomson Reuters I/B/E/S.

It said cost savings from this restructuring program

should be around $300 million to $400 million per year. Allergan currently employs 18,000 people, according to its website. RBC Capital Markets analyst Randall Stanicky said the savings should add around 75 cents to $1 of earnings per share support going forward.

In November, the company said it was working on a program to expand its base business and reduce costs so it could return to earnings growth by 2019, but did not disclose a specific strategy at that point.

Allergan worked hard in recent years to protect Restasis, which generated about $1.5 billion in sales in 2016, from generic rivals. It struck a controversial deal with a Native American tribe in September to shield review of the patents by U.S. regulators, drawing the ire of lawmakers and rival drug companies.

But in October, a Texas federal judge invalidated Restasis patents on grounds that they cover ideas that are obvious, making it possible for rival generics to hit the market as early as next year. Allergan has appealed the ruling.

Shares of Allergan rose $1.02, or 0.6 percent, to $171.34 in afternoon trading on Wednesday.

(Reporting by Michael Erman; Editing by Chizu Nomiyama, Alistair Bell and David Gregorio)

By Michael Erman

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
11:08a AMGEN : EC approves Amgen's biosimilar Avastin
01/18 ALLERGAN : European Commission Approves Amgen And Allergan's MVASI® (Biosimilar ..
01/17 Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS P..
01/17 Allergan Pact Advances -- WSJ
01/17 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareh..
01/16 ALLERGAN : Ironwood and Allergan Announce Settlement with Sun Pharma Resolving L..
01/13 ALLERGAN : Evolus Files for IPO Ahead of Potential 2018 Approval for Botox Alter..
01/11 ALLERGAN : 2 Reasons Why Allergan Stock Plunged in 2017
More news
News from SeekingAlpha
01/18 EC OKs Amgen's Avastin biosimilar
01/18 Big Biopharma in the red in early trade
01/16 ALLERGAN : Insiders Buy; Investors Shy Away
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Ironwood and Allergan settle Linzess patent infringement suit with Sun Pharma
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 642 M
Net income 2017 -6 499 M
Debt 2017 24 894 M
Yield 2017 1,59%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,33x
EV / Sales 2018 5,40x
Capitalization 59 745 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 217 $
Spread / Average Target 21%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC9.22%59 745
JOHNSON & JOHNSON5.11%394 542
NOVARTIS1.02%227 089
PFIZER1.05%218 162
ROCHE HOLDING LTD.-5.33%211 361
MERCK AND COMPANY10.24%169 287